Nasdaq

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology ...

Poster Presentation Title: Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II ...
Seeking Alpha

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of ...

NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics (TGTX), Inc. , today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® ...
Seeking Alpha

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American ...

NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics (TGTX), Inc. , today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ...